Rac1: A potential radiosensitization target of human nasopharyngeal carcinoma CNE2 cells.
Damage of mitochondria
Poorly differentiated nasopharyngeal carcinoma
Rac1
Radiosensitivity
Journal
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982
Informations de publication
Date de publication:
01 Aug 2020
01 Aug 2020
Historique:
received:
11
11
2019
revised:
05
05
2020
accepted:
11
05
2020
pubmed:
27
5
2020
medline:
22
6
2021
entrez:
27
5
2020
Statut:
ppublish
Résumé
Radiotherapy has a high cure rate for early nasopharyngeal carcinoma(NPC). However, the radiation resistance of poorly differentiated NPC cells impacts the effectiveness of treatment of early-stage NPC patients. Here, we explored the relationship between Ras-related C3 botulinum toxin substrate 1(Rac1) expression and NPC radiosensitivity. In vitro and in vivo studies revealed that upregulation of Rac1, when combined with X-ray treatment, increased growth inhibition and induced remarkable morphological changes and apoptosis in CNE2 cells. Furthermore, rupturing of the cell and nuclear membranes, degeneration of the cristae and significant swelling of the mitochondria were observed, which were consistent with the high apoptotic rate. The Rac1(+) cells exhibited approximately 50% more migration compared with that of the NC and Rac1(-) cells. The overexpression of Rac1 can increase the radiation sensitivity of NPC CNE2 cells, and the mechanism may be closely related to the oxidative damage of mitochondria. Rac1 might be a potential target for radiosensitization in poorly differentiated NPC.
Identifiants
pubmed: 32454130
pii: S0928-0987(20)30167-6
doi: 10.1016/j.ejps.2020.105378
pii:
doi:
Substances chimiques
RAC1 protein, human
0
rac1 GTP-Binding Protein
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105378Informations de copyright
Copyright © 2020. Published by Elsevier B.V.